Cite
HARVARD Citation
O'Brien, M. et al. (2022). Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet oncology. 23 (10), pp. 1274-1286. [Online].